A PHASE 1/2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF IGM-2323 IN SUBJECTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMAS

Registry ID

IGM-2323-001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

IGM BIOSCIENCES, INC.

Start date

2022-11-30

Last update

2022-01-28

Conditions

• NON-HODGKIN LYMPHOMA

Related clinical trials

• A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-1045 MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH NON-HODGKIN LYMPHOMA
• AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
• A PHASE 1 TRIAL OF BTM-3566 IN RELAPSED/REFRACTORY MATURE B CELL LYMPHOMAS AND ADVANCED SOLID TUMORS
• A PHASE 1 FIRST-IN-HUMAN STUDY OF ARV-393 IN ADULT PARTICIPANTS WITH ADVANCED NON-HODGKIN'S LYMPHOMA
• NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF ENSARTINIB IN PATIENTS WITH TUMORS HARBORING ALK OR ROS1 GENOMIC ALTERATIONS
• A PHASE I COHORT DOSE ESCALATION AND EXPANSION TRIAL TO DETERMINE THE SAFETY, TOLERANCE, MAXIMUM TOLERATED DOSE, AND PRELIMINARY ANTINEOPLASTIC ACTIVITY OF IKS03, A CD19-TARGETING ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH ADVANCED B CELL NON-HODGKIN LYMPHOMAS (NHL)

View on source registry